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Immunopathogenesis of Chlamydial
Pelvic Inflammatory Disease:
The Role of Heat-Shock Proteins
Editorial
Pelvic inflammatory disease (PID) is the most important complication of sexually
transmitted chlamydial infections, causing major medical, social, and economic
problems. PID is an ascending infection, with well over half of the cases caused by
Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), or both. However, other
microorganisms representing abnormal vaginal flora, such as those present in
bacterial vaginosis, are also commonly involved.
,2 GC rates have rapidly de-
creased in most developed countries, while CT rates have remained high. Thus,
the relative role of CT in the etiology of PID has increased. In the 1980s, it also
became obvious that the clinical spectrum ofPID manifestations was changing. An
increasing proportion of cases were atypical or silent, and the typical "textbook"
PID was becoming a rare disease. Subsequently, there has been a dramatic drop in
the incidence of inpatient PID. Clearly, this change reflects a change in the
etiologic pattern ofPID.
A large number of seroepidemiologic studies support the concept of silent PID
by demonstrating a strong link between serum antibodies to CT and tubal factor
infertility or ectopic pregnancy in patients with or without histories of PID.
Concern about the problem of unrecognized PID has also led to a fundamental
change in the recommendations for PID diagnosis. The following set of simple,
easily ascertained minimum clinical criteria should trigger antibiotic treatment for
probable PID: lower abdominal tenderness; bilateral adnexal tenderness; cervical
motion tenderness; no evidence of a competing diagnosis, e.g., positive pregnancy
test, acute appendicitis.
4 This important change in direction, from a laboratory-
and laparoscopy-based diagnosis toward a syndromic diagnosis, should increase
sensitivity by decreasing the false-negative rate. Although the more sensitive
approach will result in some unnecessary antibiotic treatment, it will also lead to the
provision of proper therapy earlier in the course of PID. Delay of care, as well as
unrecognized PID, is an important cause of impaired fertility, particularly in
chlamydial PID. s
Worldwide, the magnitude of PID-related morbidity is still enormous. The
proportion of tubal factor infertility of all infertility ranges from 37% in developed
countries to 85% in developing countries.
6 Our understanding of the pathogenesis
ofPID and PID-related sequelae has increased along with a better understanding
of the immunopathogenesis of CT infection. Early studies had already suggested
that a single acute infection per se could not account for all the pathology associated
with chlamydial disease.
7 The persistence of chronic inflammation after proper
therapy for chlamydial infection has been a puzzling phenomenon in many clinical
studies. For instance, persistent cervicitis not explained by relapse or reinfection
was found 3 months after therapy in 23-33% of women treated for chlamydial
mucopurulent cervicitis. Similarly, not only adhesion formation and tubal occlu-
sions but also persistent inflammation of the fallopian tubes in the absence of CT
were frequently seen during a second-look laparoscopy performed 4-6 months
after the index episode.
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The main sources of a repeat or prolonged antigenic stimulus leading to systemic
sensitization against chlamydiae are the persistence of subclinical infection after
unsatisfactory treatment and recurrent infection. Subclinical PID (plasma-cell
endometritis) has been detected in two-thirds of women with chlamydial mucopu-
rulent cervicitis. 2’ 10 Poor compliance with antibiotic therapy is a major problem,
increasing the risk of persistent infection.
11 In a survey of general practitioners in
Norway, 63 different regimens were used for the treatment ofPID. Only 46% of
these regimens were compatible with standard treatment guidelines.
12 Similarly,
recurrent infections are extremely common, particularly among adolescents.
13,14
CT is a strong immunogen that stimulates both humoral and cell-mediated
immune responses.
15 This organism can induce perturbations in immune function
that may assist its survival in an infected host.
16 The ability ofCT to convert from
resting to replicating infectious forms within host cells creates increasing difficul-
ties in eliminating this microbe. Ifthe first line ofimmune surveillance against CT
fails (Langerhans cells, macrophages, naturally occurring or specific secretory
antibodies), the invasion of chlamydiae results in infection of epithelial cells and
fibroblasts. Infected cells release chlamydiae, and increasing numbers of these
organisms enter lymphoid tissue, a situation characterized by striking polyclonal
B-cell hyperplasia. 2’ 10,17,18 The release of large quantities of chlamydial particles
from infected cells leads to a perturbation of the immune response. Our recent
findings suggest that in moderate plasma-cell endometritis, proliferating T cells
stimulate a specific antibody response, but in severe endometritis, they downregu-
late [type-1 helper T cell (Th 1-type) response] or upregulate (Th2-type response)
polyclonal antibody production (Lehtinen M, Rantala I, Aine R, Paavonen J,
unpublished data, 1994). Thus, the indication of a Th 1- or Th2-type response may
be an important determinant in chlamydial disease pathogenesis. Of the proliferat-
ing T cells, Thl cells regulate classic delayed hypersensitivity (DHS) reactions.
The cytokine profile of a type-1 helper pathway (dominant cell-mediated response)
is different from that of a type-2 helper pathway (dominant antibody response).
Interferon (IFN)-gamma and interleukin 2, in particular, play major roles in
turning on the efferent arm of cell-mediated immunity. High levels of IFN-
gamma have been detected in endocervical secretions of patients with chlamydial
cervicitis19 and in sera of patients with PID.
2 However, in vitro studies have
shown that IFN-gamma mediates the development of atypical morphologically
enlarged chlamydial forms. Such forms display greatly reduced levels of outer-
membrane proteins such as MOMP, 60-kD OMP, and lipopolysaccharide, but a
continued production of heat-shock protein (HSP) 60. 21’22 If IFN-gamma in-
duces similar abnormal persistent organisms in vivo, such persistently infected
cells could augment the pathogenesis of the chronic chlamydial sequelae that follow
chlamydial infection by serving as depots of antigen capable of stimulating chronic
inflammation.
We now know that the chronic sequelae of chlamydial infection are caused by a
DI--IS reaction to chlamydial HSPs, particularly the 57-kD EISP. HSPs serve as
important antigens of infectious agents and are among the most conserved mole-
cules in phylogeny.
23 The predominant chlamydial stress proteins belong to the
12-kD (or GroES-like) HSP family, 60-kD (or GroEL-like) HSP family
(HSP60), and 70-kD (or DnaK-like) HSP family (HSP70). The amino acid
homology of the EISPs with their microbial or human counterparts is high,
varying from 42 to 90% (Table 1).
24-27
A number of studies have looked at the antibody responses to HSPs induced by
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TABLE I. Amino acid sequence-deduced homology of C. trachomatis L2 HSPs with
microbial and human GroES, GroEL, and DnaK analogs
GroES GroEL DnaK
Organism (%) (%) (%)
Chlamydia trachomatis D 94
Chlamydia pneumoniae 89 95 87
Chlamydia psittaci 85 93
Coxiella burnetii 33 61
Bacillus megaterium 57
Escherichia coli 31 60 57
Mycobacterium tuberculosis 44 57
Human 48 42
aData from references 24-27.
bC. trachomatis D vs. C. pneumoniae.
CT and generally found a good correction between serum antibodies to HSP60 and
PID, tubal factor infertility, and ectopic pregnancy.
28-33 In women with chlamyd-
ial PID, a history of PID, c.ervicitis, or chlamydial infection; laparoscopically
observed tubal obstruction; laparoscopically observed tubal inflammation; and the
presence of moderate-to-severe adhesions were all associated with HSP60 antibod-
ies.
31 A correlation of antibodies to HSP60 with microimmunofluorescence anti-
bodies (toward chlamydial major outer-membrane protein antigen) has been de-
tected in some, 31’33 but not all studies.
32
The cell-mediated immune response to chlamydial HSPs has been less well
studied, although it undoubtedly plays a critical role in the DHS response. The
role ofDHS in the pathogenesis of chlamydial salpingitis has been studied in the
monkey "pocket" model.
34 Pigtailed monkeys were sensitized by inoculation of
live CT organisms into subcutaneous pockets containing salpingeal autotrans-
plants. When recombinant chlamydial HSP60 (rHSP60) was injected into pockets
either previously sensitized or not sensitized in the same monkey, a typical DHS
reaction was observed. Furthermore, a positive lymphocyte-proliferation response
of peripheral-blood mononuclear cells to rI-ISP60 was more common in women
with PID than in women without PID or in controls.
35 Interestingly, most of
those with positive responses had histories ofPID or ectopic pregnancy, suggesting
that the duration of exposure is an important variable of the CT-specific T-cell
response.
A molecular mimicry of human and chlamydial HSPs may play a role in
autoimmunity. An autoimmune response can begin even if the molecular mimicry
is not exact. The local accumulation of chlamydial HSPs and cross-reactive im-
mune response can generate an autoimmune reaction that explains part of the
inflammatory reaction and pathology seen after chlamydial PID. The presence of
human GroEL-like stress protein in the upper genital tract has been demonstrated
by immunohistochemistry using ML30 monoclonal antibody.
36 Therefore,
chlamydial and human HSP60 are candidate targets to autoimmune T cells,
although practically nothing is known of possible cross-reactive T-cell epitopes.
Recent epitope scanning studies of chlamydial HSP60 have revealed distinct B-cell
epitopes. Fifteen percent of infants with chlamydial pneumonia have shown low
levels of autoantibodies to chlamydial and human peptide-defined epitopes with
high amino acid homology.
37 However, although autoimmune reactions may play
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some role in the chronic sequelae of chlamydial infections, the DHS response
associated with persistent or recurrent infections clearly plays a more important
role.
In conclusion, tubal factor infertility and cctopic pregnancy arc important
public health problems. Understanding the interactions of chlamydiac with the
immune system is of paramount importance in the prevention of chlamydial PID.
Although chlamydial infections can bc treated with antibiotics, chlamydiac have
several properties that increase the risk for subclinical infections. These properties
arc based on immune perturbations induced by the organisms themselves. Not
surprisingly, tertiary prevention of PID has largely bccn disappointing because
substantial tubal damage has already occurred by the time any symptoms develop.
Secondary prevention means preventing lower genital-tract infection from ascend-
ing to the upper genital tract. I-Icalth care and provider behaviors play a critical
role in secondary prevention. Recent studies suggest that intervention trials with
selective screening for chlamydial infections effectively reduce the incidence of
PID.s Primary prevention involves preventing both exposure to and acquisition
of chlamydial infection. Clinicians play an important role in primary prevention
by questioning about high-risk sexual behavior, by encouraging screening tests for
those at risk, by ensuring that male sexual partners arc evaluated and treated, and
by counseling about safer sexual practices. Fortunately, not all women with chla-
mydial infections develop a DHS reaction to the HSPs. Genetically determined
au.toimmunc responses to the conserved cpitopcs of HSPs arc probably relatively
rare. However, studies of the fertility prognosis of asymptomatic women with
chlamydial cervical infections in relation to HSPd0 antibodies should bc under-
taken, and major T-cell cpitopcs of HSPs should bc defined to find out whether
specific cpitopcs arc responsible for the stimulation of type-1 and type-2 T-helper
cells or autoimmunc responses.
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